Melbourne News Today | 2 Min News | The Daily News Now!
A new $1,495 blood test for ovarian cancer is sparking debate in Australia, marketed as a way to catch the “silent killer” early—but experts warn it’s not ready for prime time. Developed by BCAL Diagnostics, the test detects cancer-related DNA fragments using AI and is targeted at high-risk individuals, not the general public. It requires a doctor’s referral and hasn’t been approved by Australia’s drug regulator. With limited research—just 42 cancer samples studied—accuracy remains uncertain, and even a 6% error rate could be dangerous for a rare disease. Medical professionals caution that sensational language may mislead people into thinking more testing equals better outcomes, while stressing that persistent symptoms should always prompt a doctor visit. With ovarian cancer survival rates at just 49%, the push for early detection is urgent—but experts insist this test needs more evidence before it can be trusted. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/c06c68f5e1506e8f
266 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af Melbourne News Today | 2 Min News | The Daily News Now!-fællesskabet!